Browse > Article
http://dx.doi.org/10.7314/APJCP.2016.17.S3.71

Association of the CYP17-34T/C Polymorphism with Pancreatic Cancer Risk  

Hussain, Shahid (Molecular Biology and Bioinformatics Research Group, Department of Bioinformatics and Biosciences, Capital University of Science and Technology)
Bano, Raisa (Molecular Biology and Bioinformatics Research Group, Department of Bioinformatics and Biosciences, Capital University of Science and Technology)
Khan, Muhammad Tahir (Molecular Biology and Bioinformatics Research Group, Department of Bioinformatics and Biosciences, Capital University of Science and Technology)
Khan, Mohammad Haroon (Molecular Biology and Bioinformatics Research Group, Department of Bioinformatics and Biosciences, Capital University of Science and Technology)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.17, no.sup3, 2016 , pp. 71-75 More about this Journal
Abstract
Pancreatic cancer is a leading cause of fatality worldwide. Several population studies have been conducted on genetic diagnosis of pancreatic cancer but the results from epidemiologic studies are very limited. CYP17A gene has a role in disease formation but its influence on pancreatic cancer is unclear. A polymorphism in the 5'UTR promoter region of CYP17A1-34T/C (A1/A2) has been associated with multiple cancers. The aim of the current study was to assess associations of this polymorphism and socio-demographic risk factors with pancreatic cancer. A total of 255 and 320 controls were enrolled in the study, and were genetically analyzed through PCR-RFLP. Statistical analysis was conducted with observed genotype frequencies and odds ratios (ORs) and 95% CIs were estimated using unconditional logistic regression. The impact of socio-demographic factors was accessed through Kaplen-Meir analysis. According to our results, the A2/A2 genotype was significantly associated with pancreatic cancer (OR=2.1, 95%CI = 1.3-3.5). Gender female (OR=2.6, 95%CI=1.8-3.7), age group 80s/80+ years (OR=2.2, 95% CI=1.2-4), smoking both former (OR=4.6, 95% CIs=2.5-8.8) and current (OR=3.6, 95% CI=2-6.7), and family history (OR=7.1; 95%CI = 4.6-11.4) were also found associated with increased risk. Current study suggests that along with established risk factors for pancreatic cancer CYP17A1-34T/C may play a role. However, on the basis of small sample size the argument cannot be fully endorsed and larger scale studies are recommended.
Keywords
CYP17A1 A1/A2 polymorphism; pancreatic cancer; PCR-RFLP; statistical analysis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Amundadottir L, Kraft P, Stolzenberg-Solomon RZ (2009). Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet, 41, 986-90.   DOI
2 Arslan AA, Helzlsouer KJ, Kooperberg C. Anthropometric measures, body mass index, and pancreatic cancer: A pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Arch Intern Med. 170, 791-802.
3 Capelle C, Solcia E, Kloppel G, Hruban RH (2000). Serous cystic neoplasms of the pancreas. World Health Organization classification of tumours. Pathology and genetics of tumours of the digestive system. IARC Press Lyon.
4 Carey AH, Waterworth D, Patel K, et al. (1994) Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet , 3, 1873-6.   DOI
5 Duell EJ, Elizabeth AHolly, Karl TKelsey and Paige MBracc (2010). Genetic variation in CYP17 A1and pancreatic cancer in a population-based case-control study in the San Francisco Bay Area. Int J Cancer, 126 , 790-5   DOI
6 Duell EJ, Holly EA (2005). Reproductive and menstrual risk factors for pancreatic cancer: a population-based study of San Francisco Bay Area women. Am J Epidemiol, 161,741-7.   DOI
7 Feigelson HS, Shames LS, Pike MC, et al (1998). BE.Cytochrome P450c17alpha gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res, 58, 585-7.
8 Feigelson, HS, Coetzee, GA, Kolonel, LN, Ross, R.K and Henderson, B.E, (1997). A Polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res, 57, 1063–5.
9 Fernandez-del CC, Jimenez RE, Steer M (2005) Surgery in the treatment of pancreatic cancer. Up To Date.
10 Hruban RH, Canto MI, Goggins M, Schulick R, Klein AP. Update on familial pancreatic cancer. Adv Surg, 44, 293-311.
11 Iodice S, Gandini S, Maisonneuve P, Lowenfels A.B (2008). Tobacco and the risk of pancreatic cancer: A review and meta-analysis. Langenbecks Arch Surg, 393, 535-45.   DOI
12 Jones S, Hruban RH, Kamiyama M, (2009). Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science, 324, 217.   DOI
13 Kemery G (2006). Pancreatic cancer. Epidemiology and pathology. Pract Gastroenterol, 30, 22-32.
14 Kloppel G, Hruban RH, Longnecker DS, Adler G Ductal (2000). Adenocarcinoma of the pancreas. World Health Organization classification of tumours: pathology and genetics of tumours of the digestive system. IARC Press X.
15 Lynch HT, Smyrk T, Kern SE (1996). Familial pancreatic cancer: A review. Semin Oncol, 23, 251-75.
16 Laethem V and Marechal R (2007). Emerging drugs for the treatment of pancreatic cancer. Expert Opin Emerg Drugs, 12, 301-11.   DOI
17 Lucenteforte E, La Vecchia C, Silverman D (2011). Alcohol consumption and pancreatic cancer: A pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol, 22,1420-6.   DOI
18 Lynch HT, Brand RE, Hogg D. Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: The familial atypical mole melanoma-pancreatic carcinoma syndrome. Cancer, 94, 84-96.
19 Murphy KM, Brune KA, Griffin C (2002). Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: Deleterious BRCA2 mutations in 17%. Cancer Res, 62, 3789-93.
20 Nedelcheva KV, Haraldsen EK, AndersonKB, et al(1994). CYP17and breast cancer risk: the polymorphism in the 50 flanking area of the gene does not influence binding to Sp-1. Cancer Res, 59, 2825-8.
21 Olson SH, Bandera EV, Orlow I (2007). Variants in estrogen biosynthesis genes, sex steroid hormone levels, and endometrial cancer: a HuGE review. Am J Epidemiol, 165, 235-45.   DOI
22 Setiawan VW, Schumacher FR, Haiman CA, et al(2007). CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiol Biomarkers Prev, 16, 2237-46.   DOI
23 Sharp L, Cardy A.H, Cotton S.C, Little J. (2006) CYP17 gene polymorphisms: prevalence and associations with hormone levels and related factors: a HuGE review. Am J Epidemiol, 160, 729-40.
24 Victor K, Chen MD, Miguel R, Arguedas MD (2004). A cost minimization analysis of alternative strategies in diagnosing pancreatic cancer. Am J Gastroenterol, 99, 2223-34.   DOI
25 Steer M (2005). Clinical manifestation, diagnosis and surgical staging of exocrine pancreatic cancer. Up To Date. Br J Cancer, 93, 740.   DOI
26 Su GH, Hruban RH, Bansal RK, (1999). Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol, 154, 1835-40.   DOI
27 Tworoger SS, Chubak J, Aiello EJ, et al. Association of CYP17. CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev, 13, 94-101.